目的 探討復(fù)方苦參注射液治療Ⅲ～Ⅳ期癌癥患者癌性疼痛的臨床效果。方法 2010年1月至2014年1月山東省胸科醫(yī)院腫瘤內(nèi)科收治的122例惡性腫瘤患者, 隨機(jī)分為治療組和對(duì)照組, 每組61例。對(duì)照組采用常規(guī)治療, 治療組在常規(guī)治療的基礎(chǔ)上加用復(fù)方苦參注射液25 mL溶于250 mL生理鹽水中靜滴, 1次/d, 兩周為1個(gè)療程。對(duì)兩組患者治療后的疼痛評(píng)分、疼痛緩解的有效率及不良反應(yīng)情況進(jìn)行評(píng)價(jià)。結(jié)果 治療后治療組患者疼痛評(píng)分降低顯著, 兩組間差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);治療組和對(duì)照組患者疼痛緩解的有效率分別為81.97%和52.45%, 差異具有統(tǒng)計(jì)學(xué)意義(P<0.05)。結(jié)論 復(fù)方苦參注射液可有效緩解Ⅲ～Ⅳ期癌癥患者癌性疼痛, 無明顯不良反應(yīng), 值得深入研究。

Objective To study the clinical analysis of therapeutic effects of Compound Sophorae Injection on the cancer pain of Ⅲ－Ⅳ stage cancer patients. Methods The clinical information of 122 cases of metastatic bone cancer patients suffered with pains was collected retrospectively from January 2010 to January 2014, these patients were selected and randomly divided into observation group (based on the conventional treatment, Compound Sophorae Injection 25 mL was added into 250 mL normal saline solution for iv drip once daily) and the control group (conventional treatment), and there were 61 patients in each group. The pain score, effective rate of pain relief, and adverse reactions were compared after treatment between the two groups. Results After the treatment, the pain scores of the patients in the two groups decreased, and the pain score of the patients in the observation group was significantly lower than that of the patients in the control group (P<0.05). The effective rates of pain relief of the patients in the observation group and the control group were respectively 81.97% and 52.45% (P<0.05). The incidence of adverse reactions was lower in the observation group than that in the control group (P<0.05). Conclusion Compound Sophorae Injection could effectively relieve the cancer pain of Ⅲ－Ⅳ stage cancer patients, and it is worth the further research in clinic.